Acadia Pharmaceuticals continues steady commercial growth driven by its products Nuplazid and Daybue, supported by a positive CHMP opinion for Daybue in Europe. The company’s upcoming phase 2 trial results for remimfanserin in Alzheimer's disease psychosis represent a high-risk, high-reward opportunity not yet reflected in its current valuation. Despite past setbacks like the failure of ACP-101 in Prader-Willi syndrome, Acadia maintains a bullish outlook based on its existing commercial products and strong cash position of $851 million. Future gains depend on successful pipeline developments or business deals, with current valuation still below the combined value of Nuplazid and Daybue.
